Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal

Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more 

December 20, 2022 1:50 AM UTC

Building on a relationship that began with a 2016 deal for bispecific NK cell engagers, Sanofi (Euronext:SAN; NASDAQ:SNY) is paying Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) €25 million up front ($26.6 million) for rights to a preclinical NK cell engager program targeting B7H3 that is based on the biotech’s Antibody-based NK Cell Engager Therapeutics (ANKET) platform. The deal includes nearly €1.4 billion in milestones. The partners have already begun clinical studies of an anti-NKp46/CD123 bispecific antibody to treat blood cancers.

Entrada Therapeutics Inc. (NASDAQ:TRDA) fell $6.39 (32%) to $13.50 in after-hours trading Monday after announcing that FDA had placed a clinical hold on one of its Duchenne muscular dystrophy (DMD) programs just three days after designating it an orphan drug. The reason for the hold was not disclosed. The program, ENTR-601-44, is a DMD exon 44 skipping oligonucleotide that leverages the company’s endosomal escape vehicle platform. On Dec. 8, Entrada announced licensing of a myotonic dystrophy type 1 (DM1) asset based on the same platform to Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). ...